A novel inhibitor of antiapoptotic BCL-2 proteins, a new promising anticancer drug candidate. Potent Bcl-2 family inhibitor. Synonyms: 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide, Navitoclax CAS NO: 923564-51-6 Molecular Formula: C47H55ClF3N5O6S3 Molecular Weight: 974.61 Purity: 98% (HPLC) Appearance: White to pale brown solid Melting Point: >124C (dec.) (lit) Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) Method for Determining Identity: Proton NMR, F NMR Spectroscopic and Mass Spectrometric Analysis Atmosphere: Inert gas Ethyl Acetate Content: As Reported Storage and Stability: Powder may be stored at -20C. Stable for 6 months after receipt at -20C. Hygroscopic. Note: Inert atmosphere is preferred for long term storage.
Molekulargewicht:
974.61
CAS Nummer:
[923564-51-6]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
